The recent discovery that normal and neoplastic epithelial cells re-enter the stem cell state raised the intriguing possibility that the aggressiveness of carcinomas derives not from their existing content of cancer stem cells (CSCs) but from their proclivity to generate new CSCs from non-CSC populations. Here, we demonstrate that non-CSCs of human basal breast cancers are plastic cell populations that readily switch from a non-CSC to CSC state. The observed cell plasticity is dependent on ZEB1, a key regulator of the epithelial-mesenchymal transition. We find that plastic non-CSCs maintain the ZEB1 promoter in a bivalent chromatin configuration, enabling them to respond readily to microenvironmental signals, such as TGFb. In response, the ZEB1 promoter converts from a bivalent to active chromatin configuration, ZEB1 transcription increases, and non-CSCs subsequently enter the CSC state. Our findings support a dynamic model in which interconversions between low and high tumorigenic states occur frequently, thereby increasing tumorigenic and malignant potential.
INTRODUCTION
Metastatic dissemination and disease relapse are critical determinants of cancer prognosis. The mechanisms underlying both processes remain poorly understood. Recent advances in understanding cellular hierarchies present within a variety of tumors have changed our perspective of neoplastic cell population organization. In particular, cell-surface antigen markers have revealed distinct subpopulations of neoplastic cells within tumors, showing pronounced differences in tumor-initiating and metastatic powers (Visvader and Lindeman, 2012) . Such evidence indicates that, within individual tumors, genetically identical cancer cells may nonetheless reside in distinct phenotypic states.
Importantly, tumors derived from implanting highly tumorigenic subpopulations of cells exhibit the phenotypic heterogeneity of their predecessor tumors in that they contain both highly and weakly tumorigenic cells (Visvader and Lindeman, 2012) . Implicit is the notion that highly tumorigenic cells can self-renew and also divide asymmetrically into daughter cells with low tumorigenic potential. Parallels identified with cell hierarchies operating in normal adult tissues have led to coining of the term ''cancer stem cell'' (CSC) to describe the subset of neoplastic cells that reside in a highly tumorigenic state.
The simplest depiction would portray CSCs as residing at the apex of a cellular hierarchy and spawning, in a unidirectional manner, more differentiated non-CSC progeny. Cells in a number of cancer types conform to that model (Bonnet and Dick, 1997; Visvader and Lindeman, 2012) . These studies imply that, once a CSC has exited the CSC state, it cannot re-enter it. This principle of unidirectionality holds great importance, given the significance of CSCs for cancer development and, quite possibly, progression to metastatic disease.
A small number of studies now suggest that not all cancers strictly conform to the unidirectional hierarchical CSC model. We and others have recently demonstrated that non-CSCs can acquire CSC-like activity under certain conditions (Chaffer et al., 2011; Gupta et al., 2011; Roesch et al., 2010) . These studies open the door to the possibility that there is likely to be greater plasticity in cancer cell populations-yielding bidirectional interconversions between CSC and non-CSC statesthan is depicted in the simplest version of the CSC model.
It has remained unclear whether these interconversions are confined to specific types of cancer, how frequently they occur in vivo, and how they are achieved mechanistically. These interconversions are potentially important for cancer diagnosis, prognosis, and therapy, given the now-extensive evidence that CSCs are intrinsically more prone to disseminate and, at the same time, exhibit resistance to many existing antitumor therapies (Dean et al., 2005; Malanchi et al., 2012) . In the present study, we aimed to address the role of non-CSC-to-CSC conversions by determining their frequency in a cohort of breast cancer (BrCa) cell lines.
In fact, we find that non-CSC-to-CSC conversions occur frequently in certain subtypes of BrCa, but not in others, and have uncovered a mechanism governing this transition. From a therapeutic standpoint, the plasticity that we describe suggests efforts to improve therapeutic outcome for cancer patients by specifically targeting CSCs must be further enhanced by coupling them with strategies designed to eliminate non-CSCto-CSC interconversions or, at the very least, to eliminate the subpopulations of non-CSCs that are poised to become CSCs.
RESULTS

CD44 Status and Tumorigenic Potential
Cell-surface antigens, such as CD44, CD24, and ESA, have been successfully used to isolate CSC-like populations from BrCa cell lines and primary tissues. Among these antigens, it is widely accepted that breast CSCs are contained exclusively in the CD44 hi cell compartment (Al-Hajj et al., 2003; Fillmore and Kuperwasser, 2008; Mani et al., 2008; Visvader and Lindeman, 2012) .
To test the notion that CD44 hi status on its own would allow enrichment of CSCs from BrCa cell lines, we analyzed five basal BrCa lines (SUM149, SUM159, HCC38, HMLER, and BPLER) and three luminal BrCa lines (MCF7, MCF7R, and T47D cells and 6-10 weeks in vivo; Figure 1A and Table S1 ). In hi components and were injected orthotopically into NOD/SCID mice (n R 8/group). Tumor incidence displayed as percentages on the graph. Data are represented as mean ± SEM. See also Figure S1 and Tables S1-S4. addition, basal CD44 hi -derived tumors were 3-to 40-fold larger than their CD44 lo counterparts when equal cell numbers were injected ( Figure 1A and Table S2 ). Limiting dilution analysis showed that basal CD44 hi cell fractions were significantly enriched for CSC frequency compared to their CD44 lo counterparts ($10-fold, Figure S1D and Table S3 ). These data demonstrate that CD44 hi expression enriches for cells that naturally reside in basal BrCa cell lines and possess higher intrinsic tumor-initiating and growth potential. Moreover, they raised the question of how certain BrCa populations that apparently lacked all traces of tumor-initiating CSCs were able to generate tumors when injected into host mice.
CD44 hi CSCs Arising from Basal CD44 lo Cell Populations In Vivo
In previous work, we demonstrated that non-CSCs derived from experimentally transformed human mammary basal epithelial cells (HMECs) could spontaneously generate de novo CSCs both in vitro and in vivo (Chaffer et al., 2011) . In the present work, we first undertook to test the idea that non-CSC-to-CSC conversions occur frequently in a broad array of BrCa cell lines.
Accordingly (Chaffer et al., 2011) . As demonstrated at the time, conversions of nontransformed immortalized human mammary epithelial cells closely paralleled the behavior of their corresponding transformed derivatives.
In this instance, we also drew from earlier work demonstrating that CD44
hi stem-like cells (SC) are more mesenchymal than their CD44 lo counterparts (Chaffer et al., 2011; Mani et al., 2008) . This and subsequent work (Guo et al., 2012) Figure 2A ). Subsequently, to identify a key mediator of non-CSC-to-CSC plasticity, we analyzed the expression of various transcription factors (EMT-TFs) known to govern the EMT program. Here we found that ZEB1 expression was significantly higher ($10-fold) in CD44 hi compared to CD44 lo cells ( Figure 2B ). To determine whether ZEB1 contributed in a critical way to mediating the transition from the CD44 lo to CD44 hi state, we analyzed CD44 lo -to-CD44 hi conversions in HME-flopc-CD44 lo cells expressing either doxycycline-inducible control or ZEB1-targeted shRNAs. We first confirmed that, following doxycycline-mediated induction, each shRNA vector was capable on its own of achieving 80%-90% ZEB1 knockdown (ZEB1-kd) in CD44 hi cells. We also noted no differences in cell proliferation between cell populations expressing the control shRNA and those expressing shRNAs targeting ZEB1 mRNA ( Figures  S2A-S2B ). We proceeded to purify CD44 lo cells expressing the various shRNA vectors by FACS, introduced them into two-dimensional (2D) cultures, and used FACS to monitor resulting cultures propagated in the presence or absence of doxycycline over the next 16 days. In the continued presence of doxycycline, the ability of CD44 lo ZEB1-kd cells to convert into the CD44 hi state was reduced by 75% (sh1) and 67% (sh2) relative to cultures expressing the control shRNA ( Figure 2C ). However, when doxycycline was withdrawn at day 8, permitting cells to continue growing in the absence of doxycycline for an additional 8 days, FACS analysis showed that CD44 lo ZEB1-kd cells soon regained their ability to convert to the CD44 hi state ( Figure 2C ). As such, the ability of CD44 lo cells to activate ZEB1 expression appeared to be an important determinant of their ability to enter into the CD44 hi state and thus an important determinant of cell plasticity in this model system.
Modulation of CD44 lo -to-CD44 hi Conversions by the
MIR200 Family
The expression of the ZEB1 gene is tightly regulated by an interactive network involving ZEB1 itself, its relative ZEB2, and members of the MIR200 family of microRNAs (Gregory et al., 2008; Wellner et al., 2009 ). Thus, ZEB1 can serve to repress expression of the MIR200 miRNAs, whereas the latter can both inhibit the function and/or reduce the stability of the mRNAs specifying ZEB1 and ZEB2; hence, these mutually antagonistic elements constitute a circuit that operates as a bistable switch, governing the residence of cells in either the mesenchymal or epithelial state. Accordingly, we confirmed that ZEB1-kd in our system resulted in a decrease in ZEB2 mRNA and concomitant increases in MIR200B and MIR200C levels ( Figures S2A and S4 ). In light of the mutually antagonistic actions of ZEB1 and the MIR200 miRNAs, we determined whether addition of synthetic lo -to-CD44 hi Cell Transitions (A) Western blot for markers of the epithelial (CDH1) or mesenchymal (CDH2, VIM) phenotype in immortalized human mammary epithelial cells (HME), HME-flopc, and single cell clones derived from HME-flopc population enriched for the CD44 lo phenotype (clones F1 and F2) or CD44 hi phenotype (clones F3 and F4).
(B) qPCR for EMT transcription factors and MIR200B/C in nontransformed CD44 lo (HME and HME-flopc-CD44 lo ) or HME-flopc-CD44 hi cells.
(C) FACS analysis for the ability of HME-flopc-CD44 lo cells to switch to the CD44 hi cell state. Cells express a doxycycline (dox)-inducible control shRNA (control) or shRNA targeting ZEB1 (sh1 and sh2). À/À, no dox; +/À, dox on for 8 days then removed for the remaining 8 days; +/+, dox on for the duration of the experiment. Inhibition (%) at day 16 is also shown (*p < 0.0001, **p < 0.0008, compared to À/À).
(D) Purified HME-flopc-CD44 lo cells treated with MIR200B/C inhibitors (I) or mimetics (M) to determine effects on switching from CD44 lo to CD44 hi cell state. Data are mean ± SEM. (E) Purified HME-flopc-CD44 lo cells expressing a dox-inducible control shRNA (control) or shRNA targeting ZEB1 (sh1, sh2, or sh3) were analyzed for their ability to switch to the CD44 hi state in the presence (+) or absence (-) of dox and in response to a MIR200C inhibitor (I) or mimetic (M).
(F) Transformed HME-flopc-CD44 lo cells (with SV40-Early Region and RAS oncoprotein) expressing a dox-inducible shRNA targeting ZEB1 (sh1) were analyzed for conversion to the CD44 hi state in the presence (+) or absence (-) of ZEB1 knockdown. Cells were monitored by FACS for 8 days.
Data are represented as mean ± SEM. See also Figure S2 .
inhibitors or mimetics (chemically synthesized, single-stranded, modified RNAs) influenced spontaneous CD44 lo -to-CD44 hi conversions in HME-flopc-CD44 lo cells. Indeed, as we found, miR200b or miR200c inhibitors significantly increased the rate of CD44 lo -to-CD44 hi conversions ( Figure 2D ).
We next undertook to determine whether the ability of the MIR200 family to affect CD44 lo -to-CD44 hi conversions derived largely from modulation of ZEB1 transcript levels or, alternatively, from the involvement of other MIR200 targets. Here we found that, in the presence of ZEB1-kd, the miR200c inhibitor was unable to provoke a CD44 lo -to-CD44 hi conversion ( Figure 2E ).
Together, these various results highlight two important points: (1) ZEB1 is a key mediator of spontaneous CD44 lo -to-CD44 hi conversions in nontransformed HMECs, acting through repression of the MIR200 family and, quite possibly, other still-unidentified targets and (2) MIR200 family modulation of CD44 lo -to-CD44 hi conversion derives from effects on ZEB1 mRNA levels.
We extended these observations by examining the consequences of ZEB1 knockdown in HME-flopc-CD44 lo cells that had previously been transformed with SV40-Early Region and oncogenic RAS in vitro ( Figure 2F ). We found that similar dynamics observed previously in the untransformed HME-flopc cells operated in their transformed derivatives.
Together, these results demonstrat that ZEB1 is a key mediator of CD44 lo -to-CD44 hi conversions in both nontransformed and transformed HMECs in vitro and support the previously reported notion that the dynamics of epithelial versus mesenchymal plasticity are quite similar in hTERT-immortalized cells and their transformed derivatives (Chaffer et al., 2011 Figure 3A ). Given the tight regulatory loop between ZEB1 and the MIR200 family, we next examined how ZEB1 protein levels are regulated in these BrCa cell lines. Accordingly, we analyzed ZEB1, MIR200B, and MIR200C mRNA expression levels. We found that luminal lines expressed very low levels of ZEB1 mRNA and very high levels of MIR200B/C. Conversely, basal CD44 lo cells generally expressed modest but nonetheless detectable levels of both ZEB1 mRNA and MIR200B/C, whereas basal CD44 hi cells expressed high levels of ZEB1 mRNA and low-toabsent MIR200B/C levels ( Figures 3B and 3C ). We further confirmed that these patterns of ZEB1 and MIR200B/C differential expression were maintained in the basal ExV-CD44 lo and
ExV-CD44 hi cell populations ( Figure S3A ). These observations demonstrate that, as predicted from their known interactions, the expression of ZEB1 and MIR200B/C varies inversely in these various BrCa cell lines and that the ZEB1 EMT-TF is expressed at far higher levels in basal BrCa cells, which represent a class of tumors that generally carry worse clinical prognosis. Moreover, they indicated that the expression pattern initially observed in the HME-flopc cells lines was closely echoed by the human basal BrCa lines examined.
Role of ZEB1-Mediated CD44 lo -to-CD44 hi Conversions in Tumor Initiation and Growth The data implicating ZEB1 in CD44 lo -to-CD44 hi cell plasticity in vitro did not shed light on whether it plays a similar role in vivo, specifically in basal BrCa cells. Consequently, we introduced the same doxycycline-inducible control or ZEB1-targeted shRNAs used earlier into cell populations of the HCC38 and SUM159 human breast cancer cell lines and the experimentally transformed HMLER cells ( Figure S3B ). We confirmed that ZEB1-kd achieved in the presence of doxycycline did not affect cell proliferation rates in monolayer culture ( Figure S3C ). FACS-purified CD44 lo populations of control or doxycycline-induced ZEB1-kd cells were then injected orthotopically into NOD/SCID mice immediately following FACS purification in order to analyze the effects of ZEB1-kd on CD44 lo -to-CD44 hi conversions in vivo and on tumorigenicity. Animals were administered doxycycline (2 g/1 L) for the duration of the experiment. Strikingly, HMLER-CD44 lo cells gave rise to tumors of 0.1 g on average after 8-10 weeks of growth in vivo, whereas their ZEB1-kd counterparts failed to form tumors ( Figure 3D ), indicating that ZEB1-mediated CD44 lo -to-CD44 hi conversions were essential for tumor-initiating potential. That is, the ability of HMLER-CD44 lo carcinoma cells to initiate tumors appeared to depend critically on the ability of these cells to spontaneously generate CSCs in vivo, which depended in turn on their ability to activate expression of their own endogenous ZEB1 gene. Similar results were obtained with HCC38-CD44 lo cells. In SUM159-CD44 lo ZEB1-kd cells, tumor size was significantly decreased (0.39 g average for controls; 0.03 g and 0.18 g on average for sh1 and sh2, respectively), and tumor-initiating potential was decreased from 100% in control cells to 67% in ZEB1-kd cells. Together, these data demonstrate that the ability of CD44 lo basal BrCa cell populations to upregulate ZEB1 expression is generally a critical determinant of their tumor-initiating potential and overall tumor growth.
Role of ZEB1 in the CD44 hi Stem Cell State
Given the importance of ZEB1 in enabling spontaneous CD44 loto-CD44 hi conversions, we wondered whether the continued expression of ZEB1 was required thereafter for maintenance of the resulting CD44 hi cell state; alternatively, other regulatory loops might become activated that then obviate the need for high ZEB1 expression for initial entrance into the CD44 hi state. Accordingly, we used FACS to monitor the ability of purified nontransformed HME-flopc-CD44 hi cells to maintain their CD44 hi marker profile in culture over a 16 day period in the presence or absence of ZEB1-kd. Interestingly, we found that CD44 hi ZEB1-kd cells maintained their CD44 hi marker profile ( Figures   4A and S4) . Next, we functionally tested the SC activity of CD44 hi ZEB1-kd cells by mammosphere-forming ability in 3D culture (Dontu et al., 2003) . We found that mammosphere formation was reduced by 80%-99% compared to control. Furthermore, addition of miR200 inhibitors to CD44 hi ZEB1-kd cells could not restore mammosphere-forming ability ( Figure 4B ). Together, these data demonstrate that ZEB1 is required for initial acquisition of both CD44
hi expression and stem-like activity of CD44 hi cells and subsequent maintenance of SC activity but is not required for long-term maintenance of high cell-surface CD44 expression. We further examined the effect of ZEB1-kd in HME-flopc-CD44 hi cells that had been transformed by the introduction of (sh1 and sh2) were analyzed for tumorigenic potential. Final tumor mass and incidence are represented (n R 5/group). Data are represented as mean ± SEM. See also Figure S3 . À signifies cells that are non-CSCs. (B) Purified HME-flopc-CD44 hi cells expressing control or shRNA-targeting ZEB1 (sh1, sh2, and sh3) were assessed for mammosphere-forming ability with or without dox induction. Cells were treated with a MIR200C inhibitor (I) or mimetic (M). p < 0.001, two-way ANOVA followed by Tukey's multiple comparisons test. *, different to miR-control and miR-200c-M; **, different to miR-control and miR-200c-I. (C) Transformed HME-flopc-CD44 hi cells expressing control, sh1, or sh2 were assessed for mammosphere formation with or without dox induction (p < 0.0001, one-way ANOVA followed by Tukey's multiple comparisons test; *, different to sh(-)).
SV40-Early Region
(D) Transformed HME-flopc-CD44 hi cells (control, sh1, and sh2) were purified by FACS and implanted into the fat pad of NOD/SCID mice (n = 8/group). Tumor weight and incidence are shown. Data are represented as mean ± SEM. See also Figure S4 .
Phenotypic Plasticity and Chromatin Configuration of the ZEB1 Promoter The above-described experiments provided clear indication that ZEB1 function is necessary for the generation of CD44 hi stemlike cells from CD44 lo cells. Still, these observations did not provide insight into why ZEB1 was readily induced in basal CD44 lo cells but not in luminal CD44 lo cells. We reasoned that current models of epigenetic regulation might illuminate these differences in behavior, as global epigenetic differences have been observed between luminal and basal-type BrCa (Maruyama et al., 2011) . More specifically, we chose to use chromatin immunoprecipitation followed by quantitative real-time PCR (ChIPqPCR) to examine the chromatin state at the ZEB1 promoter. The functional state of chromatin has been defined largely by patterns of covalent modifications to the N-terminal domains of histones and is indicative of transcriptional activity. Thus, trimethylation of lysine 4 of the histone H3 subunit (H3K4me3) is associated with transcriptional initiation (Guenther et al., 2007) , dimethylation of lysine 79 of the same subunit (H3K79me2) is associated with transcriptional elongation (Mueller et al., 2007) , and the combination of H3K4me3 and H3K79me2 indicates an actively transcribed gene. In contrast, trimethylation of lysine 27 (H3K27me3) is often associated with transcriptional repression mediated by the Polycomb group of proteins (Cao et al., 2002; Czermin et al., 2002; Kuzmichev et al., 2002; Mü ller et al., 2002) .
In embryonic stem (ES) cells, the promoters of many genes encoding key developmental regulators are associated with both the permissive H3K4me3 and the restrictive H3K27me3 modifications (yielding so-called ''bivalent'' domains) (Bernstein et al., 2006) . This bivalent chromatin is thought to keep these genes repressed but nonetheless poised for rapid transcriptional activation in response to subsequent signaling decisions favoring differentiation. These findings indicate that this combination of histone modifications may be a signature of regulators that are required to rapidly switch cell state. Indeed, through publically available databases, we determined that ZEB1 maintains a bivalent chromatin configuration in ES cells ( Figure S5A ).
We speculated that ZEB1 might exhibit a bivalent chromatin state in those cells in which it was possible to switch between low and high ZEB1 expression. To pursue this notion, we first analyzed purified CD44 lo or CD44 hi HME-flopc populations.
CD44
hi cells displayed chromatin methylation patterns indicating active transcription at the ZEB1 promoter, as determined by the presence of both H3K4me3 and H3K79me2 marks ( Figures  5A and 5B ). In contrast, we found that CD44 lo cells exhibited bivalent chromatin methylation patterns at the ZEB1 promoter, as determined by the presence of both H3K4me3 and H3K27me3. These data indicate that immortalized untransformed basal mammary epithelial cells with the ability to spontaneously switch to a CD44 hi stem-like state do indeed maintain their ZEB1 promoter in a poised, bivalent configuration. We wished to extend these observations to human BrCa cell lines, including luminal, basal CD44 lo , and basal CD44 hi cell populations. Our previous data had shown that luminal cell lines express very low levels of ZEB1 mRNA ( Figures 3A and 3B ). Perhaps unsurprisingly, we found that all luminal cell lines exhibited only repressive chromatin methylation patterns at ZEB1, as determined by the presence of H3K27me3 and the relative absence of both H3K4me3 and H3K79me2 (Figure 5C ). Further, we found that the chromatin at the ZEB1 promoter in basal CD44 hi cells is characterized by the presence of H3K4me3 and H3K79me2 and the relative absence of H3K27me3, indicating active transcription. These chromatin modifications conform with our earlier expression data, indicating that all basal CD44 hi cells express high levels of ZEB1 ( Figures 3A-3C) .
Provocatively, we found that the ZEB1 promoter in basal CD44
lo BrCa cells resided in a bivalent chromatin state in which both H3K4me3 and H3K27me3 modifications were detected, much as we had found in the immortalized CD44 lo HME cells. (Mani et al., 2008; Thiery et al., 2009) . Among these signals, TGFb has been shown to potently upregulate ZEB1 expression (Gregory et al., 2011) . Accordingly, we examined whether TGFb could enhance the spontaneous CD44 lo -to-CD44 hi transitions of immortalized HMECs. Indeed, TGFb induced a dosedependent increase, whereas the SB431542 TGFb receptor inhibitor inhibited such conversions. In the context of ZEB1-kd, however, the ability of TGFb to induce transitions was abolished (Figures 6A and S6A and S6B) . Similarly, we also found that transformed HME-flopc-CD44 lo cells could not transition from the CD44 lo to CD44 hi state in response to TGFb if ZEB1 expression was inhibited ( Figure 6B ). Hence, TGFb can enhance CD44 lo -to-CD44 hi transitions in both normal and transformed cells in a fashion that is dependent upon induction of ZEB1.
To further confirm that TGFb-driven CD44 lo -to-CD44 hi conversions were achieved through ZEB1, we showed that ZEB1 mRNA was induced and inhibited by TGFb and SB431542 treatment, respectively ( Figure S6C ). As controls, we found that TGFb target genes (PAI-1 and GADD45B) were induced and repressed in these cells in response to modulation of TGFb signaling (Figure S6C ), confirming that, overall, TFGb signaling operated in these cells as anticipated.
We extended these findings to a series of human BrCa cell lines and speculated that basal CD44 lo cells, but not luminal CD44 lo cells, would readily transit to a CD44 hi state in response to TGFb. To test this notion, luminal (MCF7Ras and ZR-75-1) and basal (HMLER and HCC38) CD44 lo cells were treated for 4 days with TGFb (2 or 20 ng/ml). FACS analysis at day 4 showed that the luminal cells did not generate any CD44
hi cells in response to TGFb treatment, whereas the basal CD44 lo cells responded in a dose-dependent manner to TGFb by generating CD44 hi cells ( Figure 6C ). We further demonstrate that
TGFb stimulation led to an increase in ZEB1 protein levels (Figure S6E) . Together, these data indicate that one important contextual signal, TGFb, enhances the rate of CD44 lo -to-CD44 hi transitions in basal breast cancer CD44 lo cell populations and that this response is dependent upon induction of ZEB1 expression.
Modulation of the Chromatin Status at the ZEB1 Promoter by TGFb
Having shown that TGFb induces CD44 lo -to-CD44 hi conversions in basal CD44 lo cells, we examined whether this effect coincided directly with changes in the histone modification patterns at the ZEB1 promoter. To do so, we performed ChIP-qPCR on basal HME-flopc-CD44 lo cells expressing doxycycline-inducible ZEB1-shRNA treated with control (HCl), TGFb (2 ng/ml), or the SB431542 TGFb receptor inhibitor (10 mM).
To maintain a homogeneous CD44 lo population, performing this experiment in a ZEB1-kd intracellular environment was essential; otherwise, TGFb treatment would cause the CD44 lo cells to transition to a CD44 hi state, in which case, the CD44 hi cells harboring active histone modifications at the ZEB1 promoter would mask any changes occurring specifically in CD44 lo cells. ZEB1 knockdown in basal CD44 lo cells was induced by exposure to doxycycline for 5 days, and cells were subsequently treated with TGFb, SB431542, or control (PBS or DMSO). After an additional 5 days in the continued presence of doxycycline, FACS analysis confirmed that the CD44 lo -ZEB1-kd cells remained as pure CD44 lo populations ( Figure 6D ). We then performed ChIP-qPCR at the ZEB1 promoter to compare changes in the levels of histone modifications in control versus TGFb or SB531542 treatment. Though no significant differences in the H3K4me3 or H3K79me2 methylation patterns were observed across all treatment groups, we found that Data are mean ± SEM of biological duplicates performed as technical replicates. See also Figure S5 .
TGFb treatment did indeed lead to a marked decrease in the repressive H3K27me3 mark associated with the ZEB1 promoter in basal CD44 lo cells ( Figure 6E ). Together, these data demonstrate that TGFb enables cells to transition from the bivalent chromatin status to the active chromatin state at the ZEB1 promoter-doing so, at least in part, through the removal of the H3K27me3 repressive mark. Wishing to put into context these changes in the histone modifications at the ZEB1 promoter, we also followed changes in histone marks following control, TGFb, or SB531542 treatment at the promoters of two TGFb-responsive genes (GADD45B, PAI-1) and a TGFb-nonresponsive gene (HPRT1). We found that the magnitude of changes in histone modifications causing active transcription at known TGFb target genes closely correlates with the changes that we had previously observed at the ZEB1 promoter in response to TGFb treatment ( Figure S6D ). These data provide further evidence that ZEB1 is a bona fide TGFb target gene in these cells.
Intrinsic Responsiveness of Luminal BrCa Cells to Exogenous ZEB1
Knowing that luminal cells are indeed responsive to TGFb treatment (as determined by TGFb-mediated upregulation of pSMAD2; Figure S6E ), we reasoned that the inability of luminal cells to undergo a CD44 lo -to-CD44 hi switch in response to
TGFb treatment might be due to their inability to activate ZEB1 transcription or, quite possibly, to an intrinsic lack of responsiveness of these cells to ZEB1 signaling. To explore these alternatives, we forced expression of ZEB1 in MCF7Ras cells (Figure S6F ). We observed a progressively increasing population of CD44 hi cells in MCF7R-ZEB1 cells over a 2 week time course ( Figure 6F ). Furthermore, we found that ZEB1 overexpression increased tumorsphere formation in vitro and tumorigenicity in vivo in a dose-dependent manner ( Figures 6G and 6H ). These data indicate that, although the endogenous ZEB1 promoter in these luminal cells is repressed, it is nevertheless intrinsically responsive to this EMT-TF if its expression is forced.
Assessment of ZEB1 and MIR200B/C in Clinical Cases of Breast Cancer As described above, we found that ZEB1 pays an important role in promoting CD44 lo -to-CD44 hi conversions and in maintaining the CSC-like state in cells that already reside in the CD44 hi state.
Indeed, both of these processes contribute to enhanced tumor initiation and growth. We were interested in relating these observations to the properties of clinical cases of breast cancer. To pursue this question, we accessed data from the Cancer Genome Atlas Network (CGAN, 2012) . We first assessed the relative abundance of MIR200 family members across all breast tumors represented in the CGAN database and found that MIR200C accounts for 93% (SD = 5%) of mature miRNA in the MIR200BC family, with minority representation of the related MIR200B (6%) and MIR429 (1%) family members ( Figure 7A) ; given the dominant presence of MIR200C over its other family members, this allowed us to focus subsequent measurements on levels of MIR200C. We also found that the levels of ZEB1 and MIR200C expression are inversely correlated in basal (p = 9.4 3 10
À4
; r 2 = 0.13), luminal A (p = 2.8 3 10 À4 ; r 2 = 0.07), and luminal B (p = 6.8 3 10 À4 ; r 2 = 0.12) subtypes, but not in HER2-overexpressing BrCa cells ( Figure 7B ). We then compared the absolute abundance of ZEB1 and MIR200C in BrCa subtypes and found that, surprisingly, in contrast to the observations described above, ZEB1 mRNA appeared to be significantly more abundant in normal and luminal A BrCa subtypes compared to the basal subtype ( Figure 7C ). Given our earlier observations in cultured cells that luminal BrCa lines do not express ZEB1 and that the chromatin at the ZEB1 promoter resides in a repressed state in those same lines, we reasoned that this apparent conflict with the relatively high levels of ZEB1 and MIR200C mRNA in clinical cases of luminal A-type BrCa might be explained in either of two ways: our studies of cultured cancer cell lines failed to properly reflect the behavior of corresponding cells in living tissues, or the data in the CGAN database was confounded by strong contamination of carcinoma cells with adjacent stromal cells expressing high levels of ZEB1.
To resolve these alternatives, we analyzed ZEB1 protein expression in a tissue microarray of breast cancer biopsies (Figures 7D and S7) . We found that ZEB1 protein is present at high levels in the stromata of all breast cancer subtypes. Interestingly, however, comparison of ZEB1 protein specifically in cancer cells showed that triple-negative (TN) BrCa cells have significantly higher levels of ZEB1 protein compared to luminal A cancer cells ( Figure 7D , p = 0.017). In fact, ZEB1 was not present in the carcinoma cells of any luminal A BrCa sample examined (0/91 samples). From these data, we conclude that the strong ZEB1-positive signature produced by the TCGA analysis data in luminal A BrCa compared to TN BrCa ( Figure 7C ) is entirely attributable to stromal cells present as significant contaminants in the luminal A samples. Our data further highlight the difficulty of interpreting such global genomic analyses performed on whole-tumor digests, in which the relative representations of both carcinoma cells and stromal cells cannot be accounted for.
Together with our demonstration in BrCa cell lines that ZEB1 is the driver of the de novo generation of CSCs from non-CSC cell populations, the high expression of ZEB1 in TN BrCa cells raises the possibility that the more aggressive nature of clinical TN-type BrCa compared to luminal-type BrCa may be in part attributable to the ability of TN BrCas to readily activate ZEB1 expression in response to microenvironmental stimuli and, subsequently, to create a continuous source of highly tumorigenic CSCs.
DISCUSSION
The present work reveals that the dynamics of interconversion between epithelial non-CSC and mesenchymal/CSC states are important determinants of normal and neoplastic epithelial tissue behavior. In contrast to the widely accepted CSC model, in which CSCs give rise to non-CSC progeny in a unidirectional manner, we have demonstrated that, in certain carcinoma subtypes-notably, basal carcinomas of the breast-neoplastic cells can readily convert from a CD44 lo to a CD44 hi state (Figure 7E) . Given the strong enrichment of CSCs in the CD44 hi state and their virtual absence in CD44 lo cells (Al-Hajj et al., 2003) , this suggested an interconversion between non-CSCs and CSCs, as indeed we demonstrated directly. Our analyses indicate that this plasticity is not a universal property of all breast carcinomas. Plastic behavior was associated with four out of five basal-type BrCa cell lines, whereas luminal CD44 lo populations (four out of four) were extremely inefficient at switching from the CD44 lo -to-CD44 hi phenotype. These findings demonstrate fundamental differences in the biology driving basal-versus luminal-type tumors and suggest that the well-documented aggressive behavior of basal-type BrCas may be traced, in no small part, to this plasticity and the associated ability to generate carcinoma cells with enhanced tumor-initiating powers. The discovery of ZEB1, a well-characterized EMT-TF, as a key mediator of CD44 lo -to-CD44 hi plasticity is consistent with the idea that the epithelial-mesenchymal transition generates cells with CSC-like activity (Mani et al., 2008; Morel et al., 2008) . Although we do not rule out the possibility that other EMT transcription factors functioning upstream of ZEB1 may also drive non-CSC-to-CSC conversions, we have demonstrated that ZEB1 plays a critical, rate-limiting role in governing basal BrCa cell plasticity.
We found that the chromatin configuration associated with the ZEB1 promoter in luminal CD44 lo cells was repressed, whereas in basal CD44 lo cells it was maintained in a bivalent/poised configuration, corresponding with the respective inability and ability of these two BrCa cell types to generate de novo CSClike cells. As we argue here, differences in chromatin configuration appear to be responsible for the profound differences in cell plasticity. This yields, in turn, the interesting notion that the aggressiveness of certain breast carcinomas may not be determined by their steady-state concentrations of CD44 hi stem-like cells; instead, their content of non-CSC cells with a proclivity to readily spawn CD44 hi stem-like derivatives may strongly influence the overall malignant behavior of these tumors. Stated differently, the bivalency of the ZEB1 promoter in carcinoma cells may represent a useful prognostic parameter of tumor aggressiveness, a notion that will require extensive clinical testing and validation. Because such bivalent chromatin is already present in certain immortalized, nontransformed human mammary epithelial cells, this might suggest that the establishment of such bivalency occurs during the normal ontogeny of this lineage differentiation. The nature of ZEB1-associated poised chromatin in basal CD44 lo cells suggests that those cells may readily and efficiently re-enter a stem-like state, given the appropriate stimulus. Indeed, we demonstrated that TGFb, a well-known EMTinducing stimulus (Gregory et al., 2011) , can efficiently promote non-CSC-to-CSC conversion. The same TGFb stimulus failed to induce luminal CD44 lo cells to convert to the CSC state (Figure 7E) . Here, bivalency associated with the ZEB1 promoter permits basal-type non-CSCs to respond to the same stimulus in a qualitatively different manner than luminal type non-CSCs. In that regard, it is plausible that basal non-CSCs located in an inflammatory microenvironment that is rich in EMT-inducing heterotypic signals may respond to local stimuli by switching to a CD44 hi CSC state; the resulting cells may then significantly enhance the aggressiveness of the tumors in which they reside. At present, it seems plausible that disseminating CSCs are the principal agents of metastasis, as they are endowed with multiple traits that are essential for completion of most of the steps of the invasion-metastasis cascade (Thiery et al., 2009) . However, in light of the plasticity that we can now ascribe to basal CD44 lo non-CSCs, it is conceivable that they too may leave a primary tumor and, following arrival at secondary tissue sites, create pools of newly formed CSCs that are critical to subsequent spawning of metastatic deposits. If validated, this would suggest that certain tumors are clinically aggressive because they can dispatch non-CSCs (which are usually far more numerous than CSCs) to distant sites as founders of new metastatic colonies following non-CSC-to-CSC conversions. In the same manner, plastic basal-CD44 lo cells may also contribute to disease recurrence. These and other considerations suggest that therapies directed at preventing non-CSC-to-CSC conversions should be considered as essential components of adjuvant therapies for breast cancer patients and, quite possibly, patients suffering other types of neoplastic disease.
EXPERIMENTAL PROCEDURES Animals
All mouse studies were performed under the supervision of MIT's Division of Comparative Medicine in accordance with protocols approved by the Institutional Animal Care and Use Committee. NOD/SCID mice were bred in house. Mice were 2-4 months of age at time of injections. Tumor cells were resuspended in 20% Matrigel/MEGM (20 ml) for mammary fat pad injections. Tumors were dissected at the end of the experiment and weighed. GFP-positive lung metastases were counted from individual lobes by fluorescent microscopy.
Cell Culture Cells were cultured as described in Table S5 .
Vectors and Viral Infections pBabe SV40-ER (Zeocin), pBabe H-Ras (Puromycin), PRRL-GFP, pLVTomato vectors, production of virus, and infection of target cells have been previously described (Elenbaas et al., 2001; Shaner et al., 2004) . Infected cells were selected with Zeocin (100 mg/ml) and Puromycin (2 mg/ml). shRNA were purchased from Open Biosystems.
RNA Preparation and qRT-PCR Analysis
Total RNA was isolated using the RNeasy Micro kit (QIAGEN). Reverse transcription was performed with miScript II RT Kit; miScript and Qantitect Primer Assays were used to detect miRNAs and mRNA (QIAGEN).
ChIP-qPCR
Chromatin immunoprecipitation was performed as previously described (Lee et al., 2006) .
Mammosphere Culture
Mammosphere culture was performed as previously described (Dontu et al., 2003) .
Statistical Analysis
Data are presented as mean ± SEM. Student's t test was used to compare two groups (p < 0.05 was considered significant) unless otherwise indicated.
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